Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to $374.1.

  • ProQR Therapeutics' Shares Outstanding (Diluted Average) rose 4810.44% to $374.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $374.1, marking a year-over-year increase of 4810.44%. This contributed to the annual value of $93.2 million for FY2024, which is 632.56% up from last year.
  • Per ProQR Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $374.1 for Q3 2025, which was up 4810.44% from $237.71 recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $92.0 million in Q4 2024 and a low of $97.77 during Q1 2024
  • Its 5-year average for Shares Outstanding (Diluted Average) is $13.3 million, with a median of $304.81 in 2023.
  • Per our database at Business Quant, ProQR Therapeutics' Shares Outstanding (Diluted Average) surged by 665543012.96% in 2022 and then plummeted by 5801.33% in 2023.
  • Quarter analysis of 5 years shows ProQR Therapeutics' Shares Outstanding (Diluted Average) stood at $1098.2 in 2021, then surged by 6655430.13% to $73.1 million in 2022, then grew by 19.25% to $87.2 million in 2023, then grew by 5.54% to $92.0 million in 2024, then plummeted by 100.0% to $374.1 in 2025.
  • Its Shares Outstanding (Diluted Average) was $374.1 in Q3 2025, compared to $237.71 in Q2 2025 and $105.19 in Q1 2025.